Neurology

Elevated HbA1c/HDL-C ratios significantly increased stroke risk, even after adjusting for confounding factors, reported authors of a recent study.

Pharmacologic treatment to prevent episodic migraine should follow a sequential trial approach that considers medication cost, headache triggers, adherence, and lifestyle interventions.

Your daily dose of the clinical news you may have missed.

Tepper, principal investigator for phase 3 trials of Symbravo as acute treatment for migraine in adults, reviews the new drug's dual MOA and target patient populations.

Agitation is the most common disabling neuropsychiatric symptom experienced by individuals with Alzheimer dementia; Grossberg explains how common in this short interview.

The global burden of migraine rose by 58% between 1990 and 2021 to more than 1 billion, a pace projected to continue and most rapidly among men and young people.

An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.

Data set to be presented at ISC 2025 shows that the protective effect of propranolol was stronger for ischemic stroke compared to other stroke types.

The pivotal INTERCEPT and MOMENTUM phase 3 clinical trials served as foundational evidence for the efficacy of the combination therapy across migraine presentations.

Mariano, a well-known researcher in regional anesthesiology and acute pain medicine, talks about the Journavx difference, including the drug's safety profile.

Todd Bertoch, MD, reviews the significant findings on relief of pain from the 2 pivotal studies and lauds the remarkable safety profile of the novel nonopoid analgesic Journavx.

Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.

A single oral dose of Symbravo provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours.

Your daily dose of the clinical news you may have missed.

Cebranopadol developer Tris Pharma expects to submit an NDA to the FDA for the dual-NMR agonist to treat moderate-to-severe acute pain later this year.

The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.

The investigational and potentially first-in-class therapy may enhance AMPA receptor sensitivity to glutamate, enhancing neuronal transmission.

Your daily dose of the clinical news you may have missed.

Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.

Cardiovascular disease is still the leading cause of death in the US, driven by rising rates of obesity, diabetes, and hypertension, according to new report.

Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.

Once every four weeks maintenance dosing of lecanemab may be easier for patients and care partners to continue treatment.

When a patient with Alzheimer dementia becomes agitated, check the physical environment for a trigger before pulling the trigger on a medication, dementia expert George Grossberg, MD, recommends.

The revolutionary medications are the first new treatments for Alzheimer disease to be approved in more than 20 years and the first-ever disease-modifying drugs.